| Dr Basel Alrefai, MD | |
|
815 Lee St, Alexander City, AL 35010-2882 | |
| (256) 212-9300 | |
| Not Available |
| Full Name | Dr Basel Alrefai |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 35 Years |
| Location | 815 Lee St, Alexander City, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568523579 | NPI | - | NPPES |
| 009950200 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 18542 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Russell Medical Center | Alexander city, AL | Hospital |
| Community Hospital Inc | Tallassee, AL | Hospital |
| Clay County Hospital | Ashland, AL | Hospital |
| Entity Name | The Russell Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811913460 PECOS PAC ID: 6406754431 Enrollment ID: O20040109000579 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
| Entity Name | Basel Refai Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003843939 PECOS PAC ID: 2769433903 Enrollment ID: O20050204000763 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
| Entity Name | Imi Radiology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841696622 PECOS PAC ID: 0042538779 Enrollment ID: O20150409000953 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
| Entity Name | Central Alabama Ct Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427622844 PECOS PAC ID: 7315345196 Enrollment ID: O20211008000328 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
| Entity Name | Wound Management Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972150084 PECOS PAC ID: 5193056364 Enrollment ID: O20211027002279 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Basel Alrefai, MD 815 Lee St, Alexander City, AL 35010-2882 Ph: (256) 212-9300 | Dr Basel Alrefai, MD 815 Lee St, Alexander City, AL 35010-2882 Ph: (256) 212-9300 |
News Archive
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
› Verified 3 days ago
Dr. Joseph Arthur Deering, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1649 Highway 22 W, Alexander City, AL 35010 Phone: 256-215-5323 Fax: 256-215-5324 | |
Dr. Edward Polk Hill Iv, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3368 Hwy 280, Suite 120 Saa, Alexander City, AL 35010 Phone: 256-234-3004 Fax: 256-234-0313 | |
Dr. Adrian Alton Cargill Jr., M.B.B.S. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3368 Highway 280 Ste 209, Alexander City, AL 35010 Phone: 256-215-7474 Fax: 256-215-7475 | |
Hilary Morgan Flippo, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3368 Highway 280 Ste 214, Alexander City, AL 35010 Phone: 256-215-7460 Fax: 256-215-7457 | |
Dr. Kevin Leonard Sublett, M.D.F.A.C.C. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3368 Highway 280, Suite 130, Alexander City, AL 35010 Phone: 256-234-2644 Fax: 256-234-2704 | |
Dr. John Coley Blythe, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3185 Highway 22 West, Alexander City, AL 35010 Phone: 256-329-2640 |